Results 21 to 30 of about 2,325 (152)
Synthesis and Evaluation of AS1411-Lenalidomide-Targeted Degradation Chimera in Antitumor Therapy [PDF]
PharmaceuticalsBackground: High expression of nucleolin (NCL) on the surface of tumor cells is closely associated with disease progression and poor prognosis. The aptamer–PROTAC conjugate (APC) technology provides a novel molecular design strategy for the targeted ...
Xueling Ma +11 more
doaj +2 more sources
AS1411 aptamer modified carbon dots via polyethylenimine‐assisted strategy for efficient targeted cancer cell imaging [PDF]
Cell Proliferation, 2020 Tingting Kong +2 more
exaly +2 more sources
Molecular Therapy: Nucleic Acids, 2022 Immune-checkpoint blockade (ICB) therapy has changed the clinical outcome of many types of aggressive tumors, but there still remain many cancer patients that do not respond to these treatments.
Daniel Meraviglia-Crivelli +6 more
doaj +1 more source
Aptamer-modified carbon dots for enhancement of photodynamic therapy of cancer cells
Talanta Open, 2022 Carbon dots (CDs) have emerged as promising materials for photodynamic therapy (PDT) because of their intriguing photochemical properties, high stability, and low toxicity.
Menghui Ma +6 more
doaj +1 more source
Bioactivity of 2′-deoxyinosine-incorporated aptamer AS1411 [PDF]
Scientific Reports, 2016 AbstractAptamers can be chemically modified to enhance nuclease resistance and increase target affinity. In this study, we performed chemical modification of 2′-deoxyinosine in AS1411, an anti-proliferative G-rich oligodeoxynucleotide aptamer, which binds selectively to the nucleolin protein.
Xinmeng Fan +4 more
openaire +2 more sources
Frontiers in Pharmacology, 2023 Multifunctional nanocarrier platforms have shown great potential for the diagnosis and treatment of liver cancer. Here, a novel nucleolin-responsive nanoparticle platform was constructed for the concurrent detection of nucleolin and treatment of liver ...
Liangliang Xiang +6 more
doaj +1 more source
A Synthetic Aptamer-Drug Adduct for Targeted Liver Cancer Therapy. [PDF]
PLoS ONE, 2015 AS1411 (previously known as AGRO100) is a 26 nucleotide guanine-rich DNA aptamer which forms a guanine quadruplex structure. AS1411 has shown promising utility as a treatment for cancers in Phase I and Phase II clinical trials without causing major side ...
Thu Le Trinh +7 more
doaj +1 more source
Molecules, 2022 Hypoxia-activated prodrugs (HAPs) with selective toxicity in tumor hypoxic microenvironments are a new strategy for tumor treatment with fewer side effects.
Xuan Wang, Qing Chen, Congxiao Lu
doaj +1 more source
Intracellular Monitoring of AS1411 Aptamer by Time-Resolved Microspectrofluorimetry and Fluorescence Imaging [PDF]
Journal of Fluorescence, 2015 Time-resolved microspectrofluorimetry and fluorescence microscopy imaging-two complementary fluorescence techniques-provide important information about the intracellular distribution, level of uptake and binding/interactions inside living cell of the labeled molecule of interest.
Bok, Jiří +4 more
openaire +3 more sources
Computable structured aptamer for targeted treatment of ovarian cancer
Frontiers in Genetics, 2023 Nucleolin protein expression is higher on the ovarian cancer cell surface. AS1411, a DNA aptamer, can bind with nucleolin protein specifically. In this study, we developed HA and ST DNA tiles to assemble six AS1411 aptamers to deliver doxorubicin.
Luoshan Ruan +8 more
doaj +1 more source